老年人群中常规与大分割高剂量放疗治疗前列腺癌的疗效与安全性:CHHiP 试验的亚组分析
CHHiP 试验中 3216 例前列腺癌患者接受 74 Gy/37 次、60 Gy/20 次或 57 Gy/19 次放疗,其中 491 例(15%)年龄≥75 岁。各分割方案下,<75 岁与≥75 岁组间生化或临床失败率无差异;在≥75 岁组,5 年生化或临床失败无事件率分别为 74 Gy 组 84.7%、60 Gy 组 91%、57 Gy 组 87.7%,提示大分割有效且耐受性良好,57 Gy 方案可能在不影响疗效的前提下减轻长期副作用。
要点
- 3216 例中 491 例(15%)≥75 岁,各分割方案下<75 岁与≥75 岁组生化或临床失败率无差异。
- ≥75 岁组 5 年生化或临床失败无事件率:74 Gy 组 84.7%、60 Gy 组 91%、57 Gy 组 87.7%。
- ≥75 岁组中 60 Gy 较 74 Gy 和 57 Gy 有肠道困扰累积发生率更高的提示,57 Gy 较 74 Gy 和 60 Gy 有膀胱困扰累积发生率更低的提示。
核心结论
- 大分割放疗在≥75 岁男性中似乎耐受良好且有效。
- 57 Gy 方案可能具有优势,可能在不影响该人群疗效的情况下减轻长期副作用。
研究设计与样本
- CHHiP 试验为前瞻性随机试验,患者接受 3 至 6 个月雄激素剥夺治疗,按 1:1:1 随机分配至 74 Gy/37 次、60 Gy/20 次或 57 Gy/19 次。
- 共纳入 3216 例患者,其中 491 例(15%)年龄≥75 岁,按年龄<75 岁或≥75 岁分组比较结局。
- 毒性采用临床医生报告结局(CRO)和患者报告结局问卷评估。
主要发现
- 各分割方案下,<75 岁组与≥75 岁组的生化或临床失败率无差异。
- ≥75 岁组 5 年生化或临床失败无事件率:74 Gy 组 84.7%、60 Gy 组 91%、57 Gy 组 87.7%,大分割方案更有利。
- CRO 3 级急性肠道毒性发生率在两个年龄组均为 2%;3 级急性膀胱毒性发生率<75 岁组为 8%、≥75 岁组为 7%。
- CRO≥2 级晚期肠道副作用的 5 年累积发生率在两个年龄组相似;但≥75 岁组中 60 Gy 较 74 Gy 和 57 Gy 有肠道困扰(轻微或更重)累积发生率更高的提示。
- ≥75 岁组患者报告膀胱困扰略高于<75 岁组;≥75 岁组中 57 Gy 较 74 Gy 和 60 Gy 有膀胱困扰累积发生率更低的提示,该现象在<75 岁组不明显。
关键数值与推荐
- CHHiP 随机分组方案:74 Gy/37 次(常规分割)、60 Gy/20 次或 57 Gy/19 次,均联合 3 至 6 个月雄激素剥夺治疗。
- 年龄分组界值:<75 岁或≥75 岁。
- ≥75 岁组 5 年生化或临床失败无事件率:74 Gy 组 84.7%、60 Gy 组 91%、57 Gy 组 87.7%。
临床怎么用
- 作者认为,大分割放疗在≥75 岁男性中似乎耐受良好且有效。
- 作者认为,57 Gy 方案可能具有优势,可能在不影响该人群疗效的情况下减轻长期副作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Outcome data on radiation therapy for prostate cancer in an elderly population are sparse. The CHHiP (Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer) trial provides a large, prospectively collected, contemporary dataset in which to explore outcomes by age. METHODS AND MATERIALS: CHHiP participants received 3 to 6 months of androgen deprivation therapy and were randomly assigned (1:1:1) to receive 74 Gy in 37 fractions (conventional fractionation), 60 Gy in 20 fractions, or 57 Gy in 19 fractions. Toxicity was assessed using clinician-reported outcome (CRO) and patient-reported outcome questionnaires. Participants were categorized as aged < 75 years or ≥ 75 years. Outcomes were compared by age group. RESULTS: Of 3216 patients, 491 (15%) were aged ≥ 75 years. There was no difference in biochemical or clinical failure rates between the groups aged < 75 years and ≥ 75 years for any of the fractionation schedules. In the group aged ≥ 75 years, biochemical or clinical failure-free rates favored hypofractionation, and at 5 years, they were 84.7% for 74 Gy, 91% for 60 Gy, and 87.7% for 57 Gy. The incidence of CRO (grade 3) acute bowel toxicity was 2% in both age groups. The incidence of grade 3 acute bladder toxicity was 8% in patients aged < 75 years and 7% in those aged ≥ 75 years. The 5-year cumulative incidence of CRO grade ≥ 2 late bowel side effects was similar in both age groups. However, in the group aged ≥ 75 years, there was a suggestion of a higher cumulative incidence of bowel bother (small or greater) with 60 Gy compared with 74 Gy and 57 Gy. Patient-reported bladder bother was slightly higher in the group aged ≥ 75 years than the group aged < 75 years, and there was a suggestion of a lower cumulative incidence of bladder bother with 57 Gy compared with 74 Gy and 60 Gy in patients aged ≥ 75 years, which was not evident in those aged < 75 years. CONCLUSIONS: Hypofractionated radiation therapy appears to be well tolerated and effective in men aged ≥ 75 years. The 57-Gy schedule has potential advantages in that it may moderate long-term side effects without compromising treatment efficacy in this group.
引用
- Wilson JM, Dearnaley DP, Syndikus I, et al. The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial. Int J Radiat Oncol Biol Phys. 2018. PMID: 29722660. doi:10.1016/j.ijrobp.2018.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。